|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1995; 25:1327-1332 © 1995 by the American College of Cardiology Foundation |
Department of Cardiology, Sourasky-Tel Aviv Medical Center, Israel.
OBJECTIVES. Our aim was to determine the percent of patients with myocardial infarction who are treated with beta-adrenergic blocking agents in dosages proved to be effective in preventing death after a heart attack. BACKGROUND. In the prospective randomized trials showing that beta-blocker treatment improves survival rates after myocardial infarction, relatively high dosages of these agents were used. However, it is not known whether these dosages are used in current clinical practice. METHODS. In a retrospective analysis of clinical data from 606 consecutive survivors of myocardial infarction at four university hospitals in three countries, we assessed the number of infarct survivors receiving prospectively defined "effective dosages" of beta-blockers. We defined these dosages as those that demonstrated improved survival rates of infarct survivors who received active drug in large, prospective, double-blind, placebo-controlled trials. RESULTS. Only 58% of infarct survivors with no contraindications to beta-blockers received these drugs at the time of hospital discharge, and only 11% received dosages equivalent to > 50% of the effective dosages. Independent predictors of failure to prescribe beta-blockers to infarct survivors without contraindications to these drugs were the use of diuretic agents, transient heart failure, impaired left ventricular function and increased patient age. Among patients receiving beta-blockers, only the use of propranolol predicted prescription of a low beta-blocker dosage. CONCLUSIONS. Failure to prescribe beta-blockers after myocardial infarction is common but in most cases is not due to clear contraindications. Many patients not receiving beta-blockers belong to subgroups that would derive the greatest benefit from such treatment. Finally, even when beta-blockers are prescribed, the dosages used are considerably lower than those proved to be effective in preventing death after myocardial infarction.
This article has been cited by other articles:
|
|
 |
|
  D. Bansal, V. Gaddam, Y. W. Aude, J. Bissett, I. Fahdi, L. Garza, J. Joseph, B. Molavi, B. V. Pai, A. Sinha, et al. Trends in the Care of Patients With Acute Myocardial Infarction at a University-Affiliated Veterans Afffairs Medical Center Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 39 - 44. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Halkin, C. L. Grines, D. A. Cox, E. Garcia, R. Mehran, J. E. Tcheng, J. J. Griffin, G. Guagliumi, B. Brodie, M. Turco, et al. Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1780 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J Everly, P. C Heaton, and R. J Cluxton Jr {beta}-Blocker Underuse in Secondary Prevention of Myocardial Infarction Ann. Pharmacother., February 1, 2004; 38(2): 286 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Stafford and D. C. Radley The underutilization of cardiacmedications of proven benefit, 1990 to 2002 J. Am. Coll. Cardiol., January 1, 2003; 41(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Geraci and C. K. Haan Effect of beta blockers after coronary artery bypass in postinfarct patients: what can we learn from available literature? Ann. Thorac. Surg., November 1, 2002; 74(5): 1727 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Wu, L. Parsons, N. R. Every, and E. R. Bates Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2) J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Vetrovec Acute and Delayed Benefits of {beta}-Blockers During Coronary Intervention : True, True and Unrelated Circulation, July 11, 2000; 102(2): 147 - 148. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pilote, F. Lavoie, V. Ho, and M. J. Eisenberg Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995 Can. Med. Assoc. J., July 1, 2000; 163(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Mehta, T. J. Ruane, P. A. McCargar, K. A. Eagle, and E. J. Stalhandske The Treatment of Elderly Diabetic Patients With Acute Myocardial Infarction: Insight From Michigan's Cooperative Cardiovascular Project Arch Intern Med, May 8, 2000; 160(9): 1301 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. McCormick, J. H. Gurwitz, D. Lessard, J. Yarzebski, J. M. Gore, and R. J. Goldberg Use of Aspirin, {beta}-Blockers, and Lipid-Lowering Medications Before Recurrent Acute Myocardial Infarction: Missed Opportunities for Prevention? Arch Intern Med, March 22, 1999; 159(6): 561 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K S Spargias, A S Hall, D C Greenwood, and S G Ball beta Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study Heart, January 1, 1999; 81(1): 25 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
T. J. Wang and R. S. Stafford National Patterns and Predictors of {beta}-Blocker Use in Patients With Coronary Artery Disease Arch Intern Med, September 28, 1998; 158(17): 1901 - 1906. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. S. Gottlieb, R. J. McCarter, and R. A. Vogel Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction N. Engl. J. Med., August 20, 1998; 339(8): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. V. Barron, A. D. Michaels, C. Maynard, N. R. Every, and for the National Registry of Myocardial Infarction Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2 J. Am. Coll. Cardiol., August 1, 1998; 32(2): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Smith, B. M. Psaty, B. Pitt, R. Garg, J. S. Gottdiener, and S. R. Heckbert Temporal Patterns in the Medical Treatment of Congestive Heart Failure With Angiotensin-Converting Enzyme Inhibitors in Older Adults, 1989 Through 1995 Arch Intern Med, May 25, 1998; 158(10): 1074 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. V. Barron, S. Viskin, R. J. Lundstrom, B. E. Swain, A. F. Truman, C. C. Wong, and J. V. Selby {beta}-Blocker Dosages and Mortality After Myocardial Infarction: Data From a Large Health Maintenance Organization Arch Intern Med, March 9, 1998; 158(5): 449 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Nesto and S. Zarich Acute Myocardial Infarction in Diabetes Mellitus : Lessons Learned From ACE Inhibition Circulation, January 13, 1998; 97(1): 12 - 15. [Full Text] [PDF]
|
|
|
|
|
|
S. Gottlieb, U. Goldbourt, V. Boyko, G. Barbash, L. Mandelzweig, H. Reicher-Reiss, S. Stern, and S. Behar Improved Outcome of Elderly Patients (>=75 Years of Age) With Acute Myocardial Infarction From 1981-1983 to 1992-1994 in Israel Circulation, January 21, 1997; 95(2): 342 - 350. [Abstract] [Full Text]
|
|
|
|
|
|
P. A. McCullough, W. W. O'Neill, S. Viskin, I. Kitzis, B. Belhassen, L. Pilote, and E. J. Topol Regional Variation across the United States in the Management of Acute Myocardial Infarction N. Engl. J. Med., January 18, 1996; 334(3): 194 - 195. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
